Oncology

#AI / data analytics / healthtech / informatics #Analysis #Animal models #Assay development optimisation & technology #Biomarkers #Cell culture #Cellular & Molecular biology #Cellular assays #Clinical trials #Drug development #Drug discovery #Drug targets #Genetics / genomes #Genomics #High Content Screening #High throughput screening #Imaging #Immunology #Lead discovery #Lead optimisation #Oncology #Pharmokinetics #Protein chemistry / Proteomics #RNA #Screening #Stem cells #System biology #Systems biology #Target validation #Therapeutics #Translational #Translational chemistry

The Impact of RNAi on Drug Discovery

The Impact of RNAi on Drug Discovery By Dr Christopher P. Miller RNAi (RNA interference) is an important target validation tool that has risen to prominence since 2001. For a number of reasons, it has supplanted other pre-existing target validation tools and is now the method of choice for target… Read More

#Archive

#Academic #ADME / Tox #AI / data analytics / healthtech / informatics #Analysis #Analytical chemistry #Assay development optimisation & technology #Automation / robotics #Biochemistry #Biomarkers #Business #Cell therapy #Cellular & Molecular biology #Cellular assays #Chemical engineering #Chemistry #Clinical specialities #Clinical trials #Computational chemistry #Drug development #Drug discovery #Drug targets #Flow Cytometry #Gene therapy #Genetics / genomes #Genetics / genomics #Genomics #High Content Screening #High throughput screening #Imaging #In Silico Biology #Lead discovery #Mass spectrometry / NMR #Metabolomics #Microfluidics #Molecular medicine #Oncology #Pharmacogenomics #Pharmacology #Precision medicine #Preclinical #Protein chemistry / Proteomics #Regulatory #RNA #Screening #Stem cells #System biology #Systems biology #Target validation #Therapeutics #Toxicology

Overview of biomarkers in disease, drug discovery and development

Overview of biomarkers in disease, drug discovery and development By Professor Stephen Naylor The pharmaceutical industry and the healthcare sector are both confronted with expensive technological innovation, escalating costs and pointed questions about productivity and efficiency. The parallels between the problems of producing new therapeutic agents and treating patients afflicted… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Biomarkers #Business #Chemistry #Clinical specialities #Drug development #Drug discovery #Genetics / genomics #Genomics #High Content Screening #Immunology #Molecular medicine #Oncology #Patent Law #RNA #Screening #Stem cells

Patent Pools as a Solution to the licensing problems of diagnostic genetics – United States and European perspectives

Patent Pools as a Solution to the licensing problems of diagnostic genetics - United States and European perspectives By Dr Jorge A. Goldstein, Dr Ted J. Ebersole, Marvin C. Guthrie, Annette A. Hirschfeld and Bart J. van den Broek Advances in diagnostic genetic testing have resulted in the ability to… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Assay development optimisation & technology #Biochemistry #Biomarkers #Business #Cell therapy #Cellular & Molecular biology #Cellular assays #Chemistry #Clinical specialities #Clinical trials #Combinatorial chemistry #Drug development #Drug discovery #Drug targets #Gene therapy #Genetics / genomes #Genetics / genomics #Lead discovery #Molecular medicine #Oncology #Organic chemistry #Regulatory #RNA #Sequencing #Stem cells #Therapeutics #Toxicology

COX-2 Inhibitor Toxicity – Warning shot over pharma’s bow

COX-2 Inhibitor Toxicity - Warning shot over pharma's bow By Dr Mark Schena and Dr William Greene Human beings are complex gene machines that rely on the intricate interplay of ~25,000 genes to impart biological function. Genomic function is affected by genetic variability and environmental factors, giving rise to considerable… Read More

#Archive

#Analysis #Animal models #Assay development & optimisation #Chemical engineering #Chemistry #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Enabling technologies #Genetics / genomes #Genetics / genomics #Genomics #Imaging #Immunology #Lead discovery #Molecular medicine #Oncology #Pathology #Pharmacology #Pharmokinetics #Protein chemistry / Proteomics #Regulatory #RNA #Sequencing #Stem cells #Target validation #Toxicology

The Use and Usefulness of Transgenic Systems in the Discovery of New Medicines

The Use and Usefulness of Transgenic Systems in the Discovery of New Medicines By Professor Jan Tornell The pharmaceutical industry is faced with the challenge to deliver truly novel medicines to a market under financial pressure when pharmaceutical R&D becomes increasingly difficult and complex. This review will mainly focus on… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Analytical chemistry #Animal models #Assay development optimisation & technology #Automation / robotics #Biochemistry #Business #Cell / tissue culture #Cell culture #Cell therapy #Cellular & Molecular biology #Cellular assays #Chemical engineering #Chemistry #Clinical trials #Combinatorial chemistry #Computational chemistry #Drug development #Drug discovery #Drug targets #Gene therapy #Genetics / genomes #Genetics / genomics #Genomics #High throughput screening #Imaging #In Silico Biology #Lead discovery #Mass spectrometry / NMR #Molecular medicine #Oncology #Patent Law #Pharmacology #Preclinical #Protein chemistry / Proteomics #Regulatory #RNA #Stem cells #System biology #Systems biology #Target validation #Therapeutics #Toxicology

Systems biology, information, disease and drug discovery

Systems biology, information, disease and drug discovery By Professor Stephen Naylor Pharmaceutical companies are confronted with an urgent need to increase their lead compound and clinical candidate portfolios and to satisfy market demands for continued innovation and revenue growth. The lack of improved productivity and limited drug pipeline growth is… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Analytical chemistry #Assay development optimisation & technology #Biomarkers #Cell therapy #Cellular assays #Chemistry #Clinical specialities #Drug development #Drug discovery #Gene therapy #Genetics / genomes #Genetics / genomics #Genomics #High Content Screening #High throughput screening #Imaging #Immunology #Lead discovery #Mass spectrometry / NMR #Oncology #Protein chemistry / Proteomics #RNA #Screening #Sequencing #Stem cells #System biology #Systems biology #Therapeutics #Toxicology #Translational #Translational chemistry

Clinical Proteomics: Opportunities in drug discovery and development

By Dr Ashok R Dongre, Dr Douglas Robinson, Dr Mark E Curran and Dr Nicholas C Dracopoli Molecular profiling is becoming increasingly important as a tool for the discovery and implementation of novel biomarkers for use in drug development. Modern profiling methods permit comprehensive analysis of biological systems that allow,… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Assay development optimisation & technology #Automation / robotics #Biochemistry #Business #Cell / tissue culture #Cell culture #Cellular & Molecular biology #Cellular assays #Chemical engineering #Chemistry #Drug development #Drug discovery #Drug targets #Enabling technologies #Flow Cytometry #Genetics / genomes #High Content Screening #High throughput screening #Imaging #Immunology #Lead discovery #Medicinal chemistry #Oncology #PCR #Pharmacology #Preclinical #RNA #Screening #Stem cells #System biology #Systems biology #Toxicology

A multi-faceted approach to the advancement of cell-based drug discovery

A multi-faceted approach to the advancement of cell-based drug discovery By Dr Ralph J. Garippa Cell-based assays, particularly those involving the use of microscopic imaging, are undergoing a renaissance within many pharma and biotech drug development programmes. Much of this has to do with the licensing, partnering and co-development of… Read More

#Archive

#Academic #ADME / Tox #AI / data analytics / healthtech / informatics #Analysis #Analytical chemistry #Assay development & optimisation #Assay development optimisation & technology #Automation / robotics #Biomarkers #Business #Cellular assays #Chemical engineering #Chemistry #Combinatorial chemistry #Drug development #Drug discovery #Drug targets #Genetics / genomes #Genetics / genomics #Genomics #High Content Screening #High throughput screening #Lead discovery #Lead optimisation #Mass spectrometry / NMR #Microfluidics #Oncology #Pharmacogenomics #Preclinical #Protein chemistry / Proteomics #Regulatory #RNA #Screening #Sequencing #Target validation #Therapeutics #Toxicology

The Current Bioinformatics Analytical Software Landscape

The Current Bioinformatics Analytical Software Landscape By Charles Chang With the vast amount of biochemical data generated from experiments conducted by research laboratories around the globe, there is strong demand for software to analyse and manage the data effectively. Analytical software can be utilised to analyse virtually every single experiment,… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Animal models #Assay development optimisation & technology #Biochemistry #Business #Cell / tissue culture #Cell culture #Cell therapy #Cellular & Molecular biology #Cellular assays #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Enabling technologies #Gene therapy #Genetics / genomes #Genetics / genomics #Genomics #High Content Screening #High throughput screening #Lead discovery #Lead optimisation #Oncology #PCR #Protein chemistry / Proteomics #RNA #Screening #Stem cells #System biology #Target validation #Therapeutics #Toxicology

Using RNAi to identify and validate novel drug targets: targeting human kinases with an siRNA library

Using RNAi to identify and validate novel drug targets: targeting human kinases with an siRNA library By Andrea Kroenke, Anne Grabner, Dr Michael Hannus, Dr Christoph Sachse, Dr David Dorris and Dr Christophe Echeverri Libraries of siRNAs directed against predefined subsets of genes now offer the capacity to greatly accelerate… Read More

#Archive

#Biologics / Biotechnology #Biomarkers #Business #Clinical trials #Drug development #Drug discovery #Drug targets #Genetics / genomes #Genetics / genomics #Genomics #High Content Screening #Lead discovery #Molecular medicine #Oncology #Preclinical #Regulatory #Sequencing #System biology #Systems biology #Theranostics #Therapeutics

Fewer drugs approved, more money spent – Where’s the beef?

Fewer drugs approved, more money spent - Where's the beef? By G. Steven Burrill Three years ago, when biotech was at its Wall Street heights, personalised medicine and its promise were on everyone's lips. Billions of dollars were being put to work to make targeted medicine a reality... and genomics… Read More

#Archive

#Biochemistry #Biomarkers #Business #Cell therapy #Cellular & Molecular biology #Clinical specialities #Clinical trials #Drug development #Drug targets #Gene therapy #Genetics / genomes #Oncology #Pathology #Preclinical #RNA #Stem cells #System biology #Systems biology #Toxicology

DNA repair inhibition to treat cancer and other serious illnesses

DNA repair inhibition to treat cancer and other serious illnesses By Professor Stephen P. Jackson and Cheryl L. Bishop The stability of an organism's genome is essential for healthy functioning and survival. The information content and integrity of the genome are so important that a range of maintenance and repair… Read More

#Archive

#AI / data analytics / healthtech / informatics #Animal models #Automation / robotics #Cell / tissue culture #Cell culture #Cell therapy #Cellular & Molecular biology #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Gene therapy #Genetics / genomes #Lead discovery #Oncology #Preclinical #Protein chemistry / Proteomics #Regulatory #RNA #Stem cells #Target validation #Therapeutics

Urinary troubles for more than the ageing

Urinary troubles for more than the ageing By Dr Anthony PDW Ford The needs of younger incontinence sufferers coupled with the ageing of the baby-boomer population portend a big boost in demand for effective and well tolerated new medicines for lower urinary-tract dysfunction. This market is under-served today, presenting a… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Analytical chemistry #Animal models #Assay development & optimisation #Assay development optimisation & technology #Automation / robotics #Biologics / Biotechnology #Biomarkers #Business #Cellular & Molecular biology #Cellular assays #Chemical engineering #Chemistry #Clinical specialities #Clinical trials #Drug development #Drug discovery #Flow Cytometry #Genetics / genomes #Genetics / genomics #Genomics #High Content Screening #High throughput screening #Imaging #Immunology #Mass spectrometry / NMR #Molecular medicine #Oncology #Pathology #Preclinical #Protein chemistry / Proteomics #Regulatory #RNA #Screening #Stem cells #System biology #Systems biology #Target validation #Therapeutics #Toxicology

Protein BIOMARKER Strategies

By Dr Steven Bodovitz and Dr Scott D. Patterson The potential for parallel protein-based analyses to define a new era in diagnostics and drug development is generating considerable excitement in the field of proteomics. However, the discovery of differentially expressed proteins that correlate with a disease state or a drug… Read More

#Archive

#AI / data analytics / healthtech / informatics #Biomarkers #Business #Clinical trials #Drug development #Drug discovery #Drug targets #Genomics #Immunology #Immunology / Virology & Vaccines #Oncology #PCR #Protein chemistry / Proteomics #Regulatory #RNA

Public Relations and the Drug Discovery Industry

Public Relations and the Drug Discovery Industry By Dr Richard Franklin The use of the Public Relations (PR) industry to promote all facets of the pharmaceutical industry is on the increase. We take a brief look at the various uses of PR and the sectors that are being promoted. Public… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Assay development optimisation & technology #Biochemistry #Biomarkers #Business #Cellular & Molecular biology #Cellular assays #Chemistry #Clinical specialities #Clinical trials #Combinatorial chemistry #Drug development #Drug discovery #Drug targets #Enabling technologies #Genetics / genomes #Genetics / genomics #Genomics #High Content Screening #High throughput screening #Immunology #Mass spectrometry / NMR #Oncology #PCR #Protein chemistry / Proteomics #RNA #Screening #System biology #Systems biology #Target validation #Therapeutics #Toxicology #Translational #Translational chemistry

The Protein Biochip Content Problem

The Protein Biochip Content Problem By Dr Steven Bodovitz The protein biochip industry has a content problem that is not only slowing its development as a whole but possibly the development of the entire proteomics industry. In science, for a problem to have its own name, it needs to be… Read More

#Archive